Abstract
Intravenous immunoglobulin (IVIG) is used successfully for therapy of inflammatory and autoimmune diseases, especially in cases of conventional therapy resistance. Within the broad spectrum of immunomodulatory activities of IVIG in vitro and in vivo, the anti-idiotypic activity, neutralizing the autoimmune disease related idiotypes, is one of the main mechanism. We and others have proven that from the IVIG composition, diverse fractions of autoimmune disease specific IVIG can be affinity purified (sIVIG). This sIVIG was shown to be more efficient than the whole compound of IVIG in experimental animal models of autoimmune diseases.
The affinity purification of disease sIVIG encompasses three stages. The first stage is to construct an autoantigen column for affinity purification of the autoantibodies. In the second stage the purified autoantibodies are used to construct a new column composed of the autoantibodies. The later is utilized for affinity purification of anti-autoantibodies (anti- idiotypes) IVIG defined as autoimmune disease specific IVIG- sIVIG.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107–116
Bayry J, Thirion M, Misra N et al (2003) Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 24:S217–S221
Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721–730
Sherer Y, Levy Y, Shoenfeld Y (2002) IVIG in autoimmunity and cancer—efficacy versus safety. Expert Opin Drug Saf 1:153–158
Kazatchkine MD (1990) Anti-idiotypic suppression of autoantibodies with high dose intravenous immunoglobulins. Prog Clin Biol Res 337:411–414
Omwandho CO, Gruessner SE, Roberts TK, Tinneberg HR (2004) Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin Chem Lab Med 42:359–370
Sultan Y, Kazatchkine MD, Maissoneuve P, Nydegger UE (1984) Anti-idiotypic suppression of autoantibodies to factor VII (antihaemophilic factor) by high-dose intravenous immunoglobulin. Lancet 2:765–768
Schroeder JO, Zeuner RA, Euler HH, Löffler H (1996) High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 23:71–75
Evans MJ, Suenaga R, Abdou NI (1991) Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globuline. J Clin Immunopathol 11:291–295
Rossi F, Kazatchkine MD (1989) Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143:4104–4109
Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD (1991) Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 83:298–303
Tandon N, Jayne DR, McGregor AM, Weetman AP (1992) Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. J Autoimmun 5:557–570
Lundkvist I, van Doorn PA, Vermeulen M, Brand A (1993) Spontaneous recovery from the Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 67:192–198
Caccavo D, Vaccaro F, Ferri GM et al (1994) Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 7:537–548
Mehta YS, Badakere SS (1996) In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh mmunoglobulins. J Postgrad Med 42:46–49
DeKeyser F, DeKeyser H, Kazatchkine MD et al (1996) Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 14:587–591
Yuki N, Miyagi F (1996) Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 139:160–162
Silvestris F, Cafforio P, Dammacco F (1994) Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 97:19–25
Evans M, Abdou NI (1993) In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. Lupus 2:371–375
Shoenfeld Y, Rauova L, Gilburd B et al (2002) Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14:1303–1311
Blank M, Anafi L, Zandman-Goddard G et al (2007) The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 19:857–865
Mimouni D, Blank M, Payne AS et al (2010) Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol 162:543–549
Svetlicky N, Ortega OD, Mouthon L et al (2013) The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol 33(Suppl 1):S27–S32
Blank M, Nur I, Toub O et al (2005) Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 29:213–217
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Blank, M., Bashi, T., Shoenfeld, Y. (2014). Idiotype-Specific Intravenous Immunoglobulin (IVIG) for Therapy of Autoimmune Diseases. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1060. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-62703-586-6_18
Download citation
DOI: https://doi.org/10.1007/978-1-62703-586-6_18
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-62703-585-9
Online ISBN: 978-1-62703-586-6
eBook Packages: Springer Protocols